PL364749A1 - Metody leczenia oraz metody badań przesiewowych leku - Google Patents

Metody leczenia oraz metody badań przesiewowych leku

Info

Publication number
PL364749A1
PL364749A1 PL00364749A PL36474900A PL364749A1 PL 364749 A1 PL364749 A1 PL 364749A1 PL 00364749 A PL00364749 A PL 00364749A PL 36474900 A PL36474900 A PL 36474900A PL 364749 A1 PL364749 A1 PL 364749A1
Authority
PL
Poland
Prior art keywords
ppar delta
patient
treatment
cardiovascular diseases
delta inhibitors
Prior art date
Application number
PL00364749A
Other languages
English (en)
Other versions
PL205747B1 (pl
Inventor
Colin Neil Alexander Palmer
Helen Vosper
Charles Roland Wolf
Original Assignee
The University Of Dundee
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The University Of Dundee filed Critical The University Of Dundee
Publication of PL364749A1 publication Critical patent/PL364749A1/pl
Publication of PL205747B1 publication Critical patent/PL205747B1/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047Cells of the immune system
    • G01N33/5055Cells of the immune system involving macrophages
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/11Antisense
    • C12N2310/111Antisense spanning the whole gene, or a large part of it

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Food Science & Technology (AREA)
  • Toxicology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Cardiology (AREA)
PL364749A 1999-07-23 2000-07-19 Zastosowanie inhibitora aktywności PPARδ PL205747B1 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9917405.4A GB9917405D0 (en) 1999-07-23 1999-07-23 Methods of treatment and drug screening methods
PCT/EP2000/006986 WO2001007066A2 (en) 1999-07-23 2000-07-19 Ppar delta inhibitors for the treatment of cardiovascular diseases

Publications (2)

Publication Number Publication Date
PL364749A1 true PL364749A1 (pl) 2004-12-13
PL205747B1 PL205747B1 (pl) 2010-05-31

Family

ID=10857874

Family Applications (1)

Application Number Title Priority Date Filing Date
PL364749A PL205747B1 (pl) 1999-07-23 2000-07-19 Zastosowanie inhibitora aktywności PPARδ

Country Status (29)

Country Link
EP (1) EP1200114B1 (pl)
JP (1) JP2003505058A (pl)
KR (1) KR20020012323A (pl)
CN (1) CN1364087A (pl)
AR (1) AR027832A1 (pl)
AT (1) ATE430577T1 (pl)
AU (1) AU6825900A (pl)
BR (1) BR0012661A (pl)
CA (1) CA2378462A1 (pl)
CO (1) CO5280202A1 (pl)
CY (1) CY1109255T1 (pl)
CZ (1) CZ2002247A3 (pl)
DE (1) DE60042161D1 (pl)
DK (1) DK1200114T3 (pl)
ES (1) ES2326785T3 (pl)
GB (1) GB9917405D0 (pl)
HK (1) HK1046094B (pl)
HU (1) HUP0201966A3 (pl)
IL (1) IL147363A0 (pl)
MX (1) MXPA02000880A (pl)
MY (1) MY140626A (pl)
NO (1) NO20020326L (pl)
NZ (1) NZ573856A (pl)
PL (1) PL205747B1 (pl)
PT (1) PT1200114E (pl)
SI (1) SI1200114T1 (pl)
TR (2) TR200200211T2 (pl)
WO (1) WO2001007066A2 (pl)
ZA (1) ZA200200542B (pl)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL153543A0 (en) * 2000-07-20 2003-07-06 Bristol Myers Squibb Co PHARMACEUTICAL COMPOSITIONS CONTAINING A COMPOUND WHICH INHIBITS OR MODULATES PPARdelta (beta) ACTIVITY
WO2002070011A2 (en) * 2001-02-02 2002-09-12 Smithkline Beecham Corporation Treatment of ppar mediated diseases
GB0103809D0 (en) 2001-02-16 2001-04-04 Univ Dundee Methods
US20050171084A1 (en) * 2002-03-27 2005-08-04 Cairns William J. Methods of treatment with lxr modulators
GB0302446D0 (en) * 2003-02-03 2003-03-05 Imp College Innovations Ltd Screening for modulators of fat storage
US20070037882A1 (en) * 2003-04-22 2007-02-15 Astellas Pharma Inc. Remedy for cerebral neurodegenerative diseases using ppar agonist
AU2005289520A1 (en) * 2004-09-27 2006-04-06 Vical Incorporated Formulations and methods for treatment of inflammatory diseases
DE102006033394A1 (de) * 2006-07-13 2008-01-17 Eberhard-Karls-Universität Tübingen Universitätsklinikum Verfahren zum Auffinden von antiatherosklerotischen Substanzen
JP5367584B2 (ja) * 2007-01-08 2013-12-11 ソウル ナショナル ユニバーシティー インダストリー ファンデーション ペルオキシソーム増殖因子活性化受容体δリガンドチアゾール化合物及びこれを含有する医薬、化粧品及び健康食品組成物
CN112168820B (zh) * 2019-07-05 2023-09-29 中国科学院生物物理研究所 SRCAP ATPase抑制剂在结直肠癌治疗中的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5157025A (en) * 1991-04-01 1992-10-20 E. R. Squibb & Sons, Inc. Method for lowering serum cholesterol employing a phosphorus containing ace inhibitor alone or in combination with a cholesterol lowering drug
US5939442A (en) * 1995-06-07 1999-08-17 The Salk Institute For Biological Studies Modulations of peroxisome proliferator activated receptor-γ, and methods for the use thereof
WO1997028149A1 (en) * 1996-02-02 1997-08-07 Merck & Co., Inc. Method for raising hdl cholesterol levels
CN1234029A (zh) * 1996-08-27 1999-11-03 盐野义制药株式会社 色烯-3-羚酸衍生物
ATE462433T1 (de) * 1996-12-11 2010-04-15 Dana Farber Cancer Inst Inc Methoden und pharmazeutische zusammensetzungen zur inhibition des tumorwachstums
AU6773598A (en) * 1997-03-26 1998-10-20 Institut Pasteur Treatment of gastrointestinal disease with ppar modulators
PT1016714E (pt) * 1997-06-27 2003-09-30 Ono Pharmaceutical Co Novo adn plasmidico que compreende adn do gene reporter e sua utilizacao
CA2295930C (en) * 1997-07-24 2010-12-14 Yamanouchi Pharmaceutical Co., Ltd. Pharmaceutical compositions having cholesterol-lowering effect
US6191154B1 (en) * 1998-11-27 2001-02-20 Case Western Reserve University Compositions and methods for the treatment of Alzheimer's disease, central nervous system injury, and inflammatory diseases

Also Published As

Publication number Publication date
BR0012661A (pt) 2002-04-09
DE60042161D1 (de) 2009-06-18
CO5280202A1 (es) 2003-05-30
HK1046094A1 (en) 2002-12-27
CY1109255T1 (el) 2014-07-02
TR200501763T1 (tr) 2009-03-23
NZ573856A (en) 2010-06-25
PT1200114E (pt) 2009-07-09
TR200501763T2 (tr) 2005-08-22
TR200200211T2 (tr) 2002-06-21
CZ2002247A3 (cs) 2002-11-13
WO2001007066A3 (en) 2001-08-09
WO2001007066A2 (en) 2001-02-01
ATE430577T1 (de) 2009-05-15
EP1200114A2 (en) 2002-05-02
MY140626A (en) 2010-01-15
NO20020326D0 (no) 2002-01-22
HK1046094B (en) 2009-10-02
DK1200114T3 (da) 2009-08-03
HUP0201966A2 (en) 2002-09-28
HUP0201966A3 (en) 2005-01-28
PL205747B1 (pl) 2010-05-31
JP2003505058A (ja) 2003-02-12
SI1200114T1 (sl) 2009-10-31
EP1200114B1 (en) 2009-05-06
KR20020012323A (ko) 2002-02-15
AU6825900A (en) 2001-02-13
IL147363A0 (en) 2002-08-14
CA2378462A1 (en) 2001-02-01
CN1364087A (zh) 2002-08-14
ZA200200542B (en) 2003-07-30
GB9917405D0 (en) 1999-09-22
MXPA02000880A (es) 2003-07-14
AR027832A1 (es) 2003-04-16
NO20020326L (no) 2002-03-20
ES2326785T3 (es) 2009-10-20

Similar Documents

Publication Publication Date Title
WO1999046279A3 (en) INHIBITORS OF TYPE 5 AND TYPE 3 17β-HYDROXYSTEROID DEHYDROGENASE AND METHODS FOR THEIR USE
WO2005072409A3 (en) Method and apparatus for detecting vascular conditions with a catheter
MEP10508A (en) The use of 4-h-1-benzopyran-4-one derivatives as inhibitors of smooth muscle cell proliferation
IL156122A0 (en) Geldanamycin derivative and method of treating cancer using same
PL340096A1 (en) Methods of treating hypercoagulability states or hypoproteinaemia in respect to c protein
HK1048250A1 (zh) 在治疗充血性心力衰竭中使用的部分脂肪酸氧化抑制剂
SE9702860D0 (sv) New use
CY1109255T1 (el) Ppar δελτα αναστολεις για την αντιμετωπιση καρδιαγγειακων νοσων
WO2002000210A3 (en) Use of agents capable of reducing uric acid levels for the treatment of cardiovascular disease
IL165834A0 (en) Method for treatment of indwelling catheter occlusion using fibrinolytic metalloproteinases
GB9702943D0 (en) Wound healing
WO2004037208A3 (en) Method of thrombolysis by local delivery of reversibly inactivated acidified plasmin
AU6539000A (en) Composition and method for treating disease by increasing activated alpha2 macroglobulin in the blood and extravascular tissue
EP1447090B8 (de) Verwendung von Hyaluronidase zur Prophylaxe und Behandlung von Herz-Kreislauf-Erkrankungen
AU2003283227A8 (en) Method and means for the treatment of vascular and cardiac diseases
WO2002024144A3 (en) Use of transcription factors for treating inflammation and other diseases
IL153426A0 (en) Method of treating peripheral vascular diseases, peripheral neuropathies, and autonomic neuropathies
CZ223199A3 (cs) Použití inhibitorů COMT nebo jejich farmaceuticky vhodných solí nebo esterů pro výrobu léčiva k prevenci diabetických vaskulárních dysfunkcí
WO1999043308A3 (en) Treating pulmonary hypertension through tenascin suppression and elastase inhibition
WO2001041771A3 (de) Acetylsalicylsäure enthaltendes transdermales system zur behandlung von migräne
MY118982A (en) Method of reducing tissue damage associated with ischemia
EP1321146A3 (en) Inhibitors of type 5 and 3 17beta-hydroxysteroid dehydrogenase and methods for their use
WO2004035030A3 (en) Combinations of benzodithiazoles and cox-2 inhibitors for the treatment of pain
CA2306772A1 (en) Use of c18 to c26 aliphatic alcohols for the manufacture of a medicament in the treatment of hyperproliferative skin disorders
WO2006036804A3 (en) Methods for the treatment and prevention of diseases of biological conduits

Legal Events

Date Code Title Description
VDSO Invalidation of derivated patent or utility model

Ref document number: 387398

Country of ref document: PL

Kind code of ref document: A1

LAPS Decisions on the lapse of the protection rights

Effective date: 20110719